Standard ATG Dosing Results in Poorer Outcomes in Overexposed Patients after Ex vivo CD34(+) Selected Allogeneic Hematopoietic Cell Transplantation

Anti-thymocyte globulin (ATG) use mitigates the risk of graft rejection and graft-versus-host disease (GVHD) after allogeneic hematopoietic cell transplantation (allo-HCT), but ATG overexposure in the setting of lymphopenia negatively affects immune recovery. We hypothesized that standard empiric we...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Biol Blood Marrow Transplant
Autors principals: Scordo, Michael, Bhatt, Valkal, Hilden, Patrick, Smith, Melody, Thoren, Katie, Cho, Christina, Shah, Gunjan L., Maloy, Molly A., Papadopoulos, Esperanza B., Jakubowski, Ann A., Avecilla, Scott T., O’Reilly, Richard J., Castro-Malaspina, Hugo, Tamari, Roni, Shaffer, Brian C., Boelens, Jaap J., Perales, Miguel-Angel, Giralt, Sergio A.
Format: Artigo
Idioma:Inglês
Publicat: 2019
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7302932/
https://ncbi.nlm.nih.gov/pubmed/30831208
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.bbmt.2019.02.021
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars